Reversal effect of BM-cyclin 1 on multidrug resistance by down-regulating MRP2 in BALB/C nude mice bearing C-A120 cells

Abstract

Our previous study demonstrated that BM-cyclin 1, a traditional anti-mycoplasma drug, could effectively reverse the multidrug resistance (MDR) of C-A120 cells. The present study aims to explore the reversal effect of BM-cyclin 1 on MDR and its mechanisms in BALB/C nude mice bearing C-A120 cells. Immunoblotting analysis and reverse transcription-polymerase chain reaction (RT-PCR) were used to study the change in multidrug resistance-associated protein 2 (MRP2) induced by BM-cyclin 1. We found that the expression levels of MRP2 protein and mRNA in C-A120 cells treated with BM-cyclin 1 were reduced significantly. Chemical colorimetry revealed no significant change in the level of glutathione (GSH). In the xenograft model, the inhibitory rate of C-A120 cells growth in BM-cyclin 1 plus adriamycin (ADM) group was 52%, which was significantly higher than in control group (P<0.01). The immunoblotting and RT-PCR results conclusively demonstrated that BM-cycin 1 could significantly reduce the expression of MRP2 in transplanted tumor. In conclusion, BM-cyclin 1 could effectively reverse the MDR of C-A120 cells in vivo by suppressing the expression of MRP2.

Keywords

BM-cyclin 1 / MRP2 / multidrug resistance / in vivo

References

[1] TanB, Piwnica-WormsD, RatnerL. Multidrug resistance transporters and modulation. Curr Opi Oncol, 2000, 12(5): 450-458

[2] StepienKM, TomaszewskiM, TomaszewskaJ, et al.. The multidrug transporter P-glycoprotein in pharmacoresistance to antiepileptic drugs. Pharmacol Rep, 2012, 64(5): 1011-1019

[3] FardelO, LecureurV, GuillouzoA. The P-glycoprotein multidrug transporter. Gen Pharmacol, 1996, 27(8): 1283-1291

[4] ZhangL, MaS. Efflux pump inhibitors: a strategy to combat P-glycoprotein and the NorA multidrug resistance pump. Chem Med Chem, 2010, 5(6): 811-822

[5] KoolM, de HaasM, SchefferGL, et al.. Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. Cancer Res, 1997, 57(16): 3537-3547

[6] AbrahamI, El SayedK, ChenZS, et al.. Current status on marine products with reversal effect on cancer multidrug resistance. Mar Drugs, 2012, 10(10): 2312-2321

[7] SlotAJ, MolinskiSV, ColeSP. Mammalian multidrug-resistance proteins (MRPs). Essays in Biochem, 2011, 50(1): 179-207

[8] JedlitschkyG, HoffmannU, KroemerHK. Structure and function of the MRP2 (ABCC2) protein and its role in drug disposition. Expert Opin Drug Metab Toxicol, 2006, 2(3): 351-366

[9] SumizawaT, ChumanY, SakamotoH, et al.. Non-P-glycoprotein-mediated multidrug-resistant human KB cells selected in medium containing adriamycin, cepharanthine, and mezerein. Somat Cell Mol Genet, 1994, 20(5): 423-435

[10] WangL, SunJ, LiYQ, et al.. Reversal effect of BM-cyclin 1 on multidrug resistance in C-A120 cells. Anti-cancer Drugs, 2007, 18(9): 1015-1021

[11] SparreboomA, DanesiR, AndoY, et al.. Pharmacogenomics of ABC transporters and its role in cancer chemotherapy. Drug Resist Updat, 2003, 6(2): 71-84

[12] ColeSP, BhardwajG, GerlachJH, et al.. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science, 1992, 258(5088): 1650-1654

[13] GottesmanMM, AmbudkarSV. Overview: ABC transporters and human disease. J Bioenerg Biomembr, 2001, 33(6): 453-458

[14] ThomasH, ColeyHM. Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein. Cancer Control, 2003, 10(2): 159-165

[15] ChenQ, ZhouJ, JiangC, et al.. Reversal of P-glycoprotein-mediated multidrug resistance in SGC7901/VCR cells by PPARΓ activation by troglitazone. J Huazhong Univ Sci Technol Med Sci, 2010, 30(3): 326-331

[16] BoslingJ, PoulsenSM, VesterB, et al.. Resistance to the peptidyl transferase inhibitor tiamulin caused by mutation of ribosomal protein l3. Antimicrob Agents Chemother, 2003, 47(9): 2892-2896

[17] HogenauerG, RufC. Ribosomal binding region for the antibiotic tiamulin: stoichiometry, subunit location, and affinity for various analogs. Antimicrob Agents Chemother, 1981, 19(2): 260-265

[18] MickischGH. Multidrug resistance. 18 Mickisch GH, Multidrug resistance. Urologe A, 1996, 35(5): 370-377

[19] van ZandenJJ, GeraetsL, WortelboerHM, et al.. Structural requirements for the flavonoid-mediated modulation of glutathione S-transferase P1-1 and GS-X pump activity in MCF7 breast cancer cells. Biochem Pharmacol, 2004, 67(8): 1607-1617

[20] ChumanY, ChenZS, SetoK, et al.. Reversal of MRP-mediated vincristine resistance in KB cells by buthionine sulfoximine in combination with PAK-104P. Cancer Lett, 1998, 129(1): 69-76

[21] ChenZS, MutohM, SumizawaT, et al.. Reversal of heavy metal resistance in multidrug-resistant human KB carcinoma cells. Biochem Biophys Res Commun, 1997, 236(3): 586-590